United States Patent 7,777,050 (Drug) Patent Landscape: Scope, Claim Coverage, and Competitive Freedom-to-Operate Signals
What does US 7,777,050 claim cover in plain structural terms?
US 7,777,050 is a benzimidazole-5-carboxamide chemistry patent with a tight core scaffold and defined substituent patterning on three key loci: (i) benzimidazole nucleus substitution, (ii) anilide/aryl anilino ring substitution, and (iii) the carboxamide side-chain (alkoxy-hydroxy or substituted analogs). Claims also recite pharmaceutically acceptable salts and pharmaceutical compositions.
Claim set summary (as provided)
| Claim |
Category |
What is claimed (core elements) |
| 1 |
Compound |
Benzimidazole carboxylic acid amide with: (a) benzimidazole substitution pattern “7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethoxy)-amide” and (b) aryl anilino substitution “6-(4-bromo-2-fluorophenylamino)-…-7-fluoro…” |
| 2 |
Compound |
Same scaffold with aryl anilino ring “4-bromo-2-chloro-” and carboxamide side-chain “(2,3-dihydroxypropoxy)-amide” |
| 3 |
Compound |
Same scaffold with aryl anilino ring “4-bromo-2-chloro-” and carboxamide side-chain “(2-hydroxy-1,1-dimethylethoxy)-amide” |
| 4 |
Composition |
Composition containing compound of claim 1 plus pharmaceutically acceptable carrier |
| 5 |
Compound |
Same scaffold with aryl anilino ring “2,4-dichloro” and carboxamide side-chain “(2-hydroxyethoxy)-amide” |
| 6 |
Compound (overbroad/unclear as provided) |
“A benzoimidazole compound selected from:” with no enumerated structures beyond what is pasted; as given, it does not add clear new scope |
| 7 |
Composition |
Composition containing compound of claim 2 plus pharmaceutically acceptable carrier |
| 8 |
Composition |
Composition containing compound of claim 3 plus pharmaceutically acceptable carrier |
| 9 |
Composition |
Composition containing compound of claim 5 plus pharmaceutically acceptable carrier |
Immediate scope implication: Claims 1, 2, 3, and 5 read like enumerated Markush-style selections (specific aryl halogen patterns and specific hydroxy-alkoxy side chains) anchored to one benzimidazole substitution backbone: “7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid …-amide.” The compositions (claims 4, 7, 8, 9) are conventional product-by-formulation claims limited to containing those specific compounds.
How narrow are the structural boundaries?
1) Benzoimidazole core constraint
Across the enumerated compounds, the nucleus is consistent:
- 3-methyl-3H-benzoimidazole-5-carboxylic acid converted to an amide
- 7-fluoro retained
This means any candidate outside the “7-fluoro / 3-methyl / 5-carboxamide” framework likely avoids literal coverage.
2) Aryl anilino ring constraint (the “6-(aryl-amino)” locus)
The patent limits the aryl-amino ring substituents to specific halogen patterns:
- Claim 1: 4-bromo-2-fluoro phenylamino
- Claims 2 and 3: 4-bromo-2-chloro phenylamino
- Claim 5: 2,4-dichloro phenylamino
Practical reading: replacing any of those halogens with different substitution (e.g., moving from 2-chloro to 2-bromo, changing 4-bromo to 4-chloro, or adding a new ring substituent) is likely outside the literal claim wording. Potential equivalents arguments exist in litigation, but for infringement analysis and design-around, these enumerations act as hard boundaries.
3) Amide side-chain constraint (hydroxy-alkoxy variations)
The claims specify the amide-forming alkoxy-hydroxy side chain:
- Claim 1: (2-hydroxyethoxy)-amide (HO-CH2-CH2-O-)
- Claim 2: (2,3-dihydroxypropoxy)-amide
- Claim 3: (2-hydroxy-1,1-dimethylethoxy)-amide (t-Bu protected-like ether motif: HO-CH(CH3)2-O-)
- Claim 5: (2-hydroxyethoxy)-amide with different aryl ring
These side-chain choices cluster around hydroxyl-bearing ether linkers on the amide nitrogen substituent position. Changing chain length, removing hydroxyl functionality, converting to non-hydroxyl ether, or substituting hydroxyl with other functional groups is a primary design-around lever.
What do the claims do and do not cover?
What they cover (literal)
| Coverage type |
Where it appears |
What it means |
| Exact compounds |
Claims 1, 2, 3, 5 |
Literal infringement is strongest for the enumerated benzimidazole carboxamide structures with the specified aryl halogen patterns and the specified alkoxy-hydroxy side chains |
| Pharmaceutically acceptable salts |
Claims 1, 2, 3, 5 (and 6 as pasted) |
Salt forms of the same compounds are within scope |
| Pharmaceutical compositions |
Claims 4, 7, 8, 9 |
Formulations containing the claimed compounds plus carriers fall within scope, regardless of dosage form type, as long as they meet the “composition comprising” language |
What they do not clearly cover (based on the provided text)
- Other aryl substitutions on the phenyl ring besides the specified halogen pattern.
- Other side-chain ether/alkoxy motifs beyond those enumerated (2-hydroxyethoxy, 2,3-dihydroxypropoxy, 2-hydroxy-1,1-dimethylethoxy).
- Different benzimidazole substitution (e.g., no indication of swapping 7-fluoro for other halogens or removing 3-methyl).
- Methods of treatment (no method claims are shown in what you provided).
- General Markush broadness: claim 6 is incomplete as pasted (“selected from:” with no enumerated list), so no reliable breadth can be credited to it from the supplied claims alone.
Claim-by-claim legal scope interpretation (practical infringement mapping)
Claim 1: (4-bromo-2-fluoro phenylamino) + (2-hydroxyethoxy) amide
Scope anchor set:
1) Aryl ring: “4-bromo-2-fluorophenylamino” at the benzimidazole 6-position
2) Benimidazole: “7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid”
3) Amide side chain: “(2-hydroxyethoxy)-amide”
A compound matching all three literal elements hits claim 1. A compound matching only the core but using (for example) a 2-hydroxy-3-methoxy chain is out of the enumerated side-chain literal scope.
Claim 2: (4-bromo-2-chloro phenylamino) + (2,3-dihydroxypropoxy) amide
Key distinguishing change from claim 1:
- Aryl ring swaps 2-fluoro to 2-chloro
- Side chain changes from 2-hydroxyethoxy to 2,3-dihydroxypropoxy
This creates a practical “two-factor gate” for design-around: you can avoid claim 2 by changing either locus (aryl pattern or side chain), assuming the compound does not fall into claim 3 or claim 5.
Claim 3: same aryl as claim 2 + protected-type side chain (2-hydroxy-1,1-dimethylethoxy)
Claims 2 and 3 share:
- “4-bromo-2-chloro” aryl ring substitution
They diverge on side chain:
- Claim 2: “(2,3-dihydroxypropoxy)-amide”
- Claim 3: “(2-hydroxy-1,1-dimethylethoxy)-amide”
Design work that uses the same aryl but alters hydroxyl topology could evade claim 2 while landing in claim 3. Conversely, using the 2,3-dihydroxy chain avoids claim 3 but can still hit claim 2.
Claim 5: (2,4-dichloro phenylamino) + (2-hydroxyethoxy) amide
Claim 5 preserves the 2-hydroxyethoxy side chain used in claim 1 but changes the aryl substitution pattern:
- Claim 1 aryl: 4-bromo-2-fluoro
- Claim 5 aryl: 2,4-dichloro
This is a clean separation from claim 1 by aryl composition alone. It also shows the patent’s core motif tolerates different halogen combinations on the anilino ring while keeping the benzimidazole substitution and the ether-amide linker.
Claims 4, 7, 8, 9: compositions comprising the respective compounds
These are straightforward product claims. The key practical consequence:
- If you ship a formulation containing one of the enumerated actives (or a salt), the carrier type is largely irrelevant to infringement. The label may matter for other reasons, but under “composition comprising … pharmaceutically acceptable carrier,” any pharmaceutical dosage form containing the active is within literal scope.
How does this claim structure shape the patent landscape?
Even without method claims shown here, the compound and composition claims create a typical exclusion zone around:
1) Active ingredient identity (the specific compounds)
2) Salt forms
3) Formulated drug products that contain those compounds
Competitive landscape signals (design-around posture)
Given the enumerated nature of claims 1, 2, 3, and 5, the main competitive escape routes are structural:
- Aryl substitution changes at the 2-position and/or 4-position of the anilino ring
- Side-chain linker changes away from the listed hydroxyl-bearing alkoxy patterns
- Core benzimidazole substitution changes away from 7-fluoro-3-methyl-5-carboxamide
These are not legal strategies; they are direct consequences of claim enumeration.
What about claim 6?
The pasted text for claim 6 is incomplete:
- “A benzoimidazole compound selected from: and pharmaceutically acceptable salts thereof.”
On the record provided, claim 6 does not add identifiable structural elements or additional compound selections beyond what you supplied for claims 1, 2, 3, and 5. Treat it as not establishing additional, provable breadth from the provided excerpt.
Portfolio dynamics: where this patent likely sits relative to other claims types
Based on the form of the claims you provided, US 7,777,050 is a core chemical and formulation patent rather than:
- a broad class patent (unless claim 6 in the full document enumerates additional structures not shown here),
- a process patent,
- a method-of-use patent,
- or a delivery-system platform claim.
That placement matters because it tends to produce:
- clearer literal infringement tests for competitors who aim to match or avoid the exact enumerated scaffold,
- and a smaller need for evidentiary complexity around dosage or regimen.
Key Takeaways
- US 7,777,050 centers on a single benzimidazole scaffold: “7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid” converted to amide with specified hydroxy-alkoxy linkers.
- The primary infringement boundary is enumerated selection across three structural loci: aryl halogen pattern (2- and 4-substitution), side-chain linker (2-hydroxyethoxy vs 2,3-dihydroxypropoxy vs 2-hydroxy-1,1-dimethylethoxy), and the conserved 7-fluoro / 3-methyl / 5-carboxamide core.
- The composition claims (4, 7, 8, 9) are carrier-agnostic containment claims: any pharmaceutical product formulation containing the claimed active compound (or its salt) falls into the exclusion zone.
- From the claim text provided, claim 6 does not establish additional breadth because its enumerated selection list is missing.
FAQs
1) Which claims are most important for compound infringement?
Claims 1, 2, 3, and 5 are the core compound claims because they enumerate specific structures and include pharmaceutically acceptable salts.
2) Do the composition claims require a specific formulation technology?
No. Claims 4, 7, 8, and 9 only require a composition comprising the claimed compound and a pharmaceutically acceptable carrier.
3) What is the fastest design-around lever for literal scope?
Change at least one of the enumerated differentiators: the aryl ring halogen pattern or the hydroxy-alkoxy side-chain.
4) Can a salt design-around avoid infringement?
If the salt is a “pharmaceutically acceptable salt” of one of the claimed compounds, it remains within claims 1, 2, 3, and 5.
5) Does claim 6 expand the patent beyond the enumerated compounds you listed?
Not based on the excerpt you provided, because claim 6’s enumerated list is missing; the text does not identify additional structures.
References
- User-provided claims text for US 7,777,050 (claims 1-9).
